Aquaculture pharmaceutical group Pharmaq reported a massive spike in earnings last year, the result of huge demand for vaccines to combat salmon diseases in both hemispheres.
Demand for the pancreatic disease (PD) vaccine in the UK and Norway, along with a growing need for the company’s salmonid rickettsial septicaemia (SRS) vaccine in Chile, were “important contributions to the company's overall performance,” the company said in recently released results.
Overhalla, Norway-based Pharmaq reported a 48.7 percent jump in operating profit, to NOK 244.5